On July 13, 2026, Mesoblast Limited, a global leader in allogeneic cellular medicines for inflammatory diseases, revealed that it has successfully treated over 300 patients in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) linked with degenerative disc disease. The goal of the trial is to validate the long-lasting pain relief achieved through a single intra-discal injection of rexlemestrocel-L as demonstrated in the prior MSB-DR003 trial. Mesoblast Limited's stocks are listed as Nasdaq:MESO and ASX:MSB.